|  |
| --- |
| **Supporting Table 1**: Joinpoint incidence trends for top 15 cancers for all races/ethnicities combined by sex, 1999–2014 |
|  | Joinpoint Analyses (1999–2014)†  |
|  | Trend 1 |  | Trend 2 |  | Trend 3 |  | AAPC‡  |
| Sex/Cancer Site or Type | Years | APC§  |  | P |   | Years | APC§  |  | P |   | Years | APC§  |  | P |   | 2010–2014 | P |
| All sites|| |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Both sexes | 1999-2008 | -0.3 |  |  .06 |  | 2008-2014 | -1.0 | ¶  |  .001 |  |  |  |  |  |  | -1.0 | ¶  |  .001 |
|  Males | 1999-2008 | -0.6 | ¶  |  .003 |   | 2008-2014 | -2.2 | ¶  | <.001 |   |  |   |   |   |   | -2.2 | ¶  | <.001 |
|  Females | 1999-2014 | 0.0 |  |  .96 |  |  |  |  |  |  |  |  |  |  |  | 0.0 |  |  .96 |
|  Children (ages 0–14) | 1999-2014 | 0.8 | ¶  | <.001 |   |  |   |   |   |   |  |   |   |   |   | 0.8 | ¶  | <.001 |
|  Children (ages 0–19) | 1999-2014 | 0.8 | ¶  | <.001 |  |  |  |  |  |  |  |  |  |  |  | 0.8 | ¶  | <.001 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Top 17 cancers for males\*\* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Prostate | 1999-2009 | -1.4 | ¶  |  .01 |  | 2009-2014 | -7.6 | ¶  | <.001 |  |  |  |  |  |  | -7.6 | ¶  | <.001 |
|  Lung and bronchus | 1999-2008 | -1.6 | ¶  | <.001 |   | 2008-2011 | -3.1 | ¶  | <.001 |   | 2011-2014 | -2.2 | ¶  | <.001 |   | -2.4 | ¶  | <.001 |
|  Colon and rectum | 1999-2003 | -2.1 | ¶  |  .001 |  | 2003-2012 | -3.4 | ¶  | <.001 |  | 2012-2014 | -0.5 |  |  .75 |  | -1.9 | ¶  |  .004 |
|  Urinary bladder | 1999-2005 | -0.1 |   |  .73 |   | 2005-2014 | -0.8 | ¶  | <.001 |   |  |   |   |   |   | -0.8 | ¶  | <.001 |
|  Melanoma of the skin | 1999-2014 | 2.3 | ¶  | <.001 |  |  |  |  |  |  |  |  |  |  |  | 2.3 | ¶  | <.001 |
|  Non-Hodgkin lymphoma | 1999-2005 | 0.8 | ¶  |  .004 |   | 2005-2014 | -0.2 |   |  .11 |   |  |   |   |   |   | -0.2 |   |  .11 |
|  Kidney and renal pelvis | 1999-2007 | 3.3 | ¶  | <.001 |  | 2007-2011 | -0.1 |  |  .75 |  | 2011-2014 | 1.6 | ¶  |  .007 |  | 1.1 | ¶  |  .001 |
|  Leukemia | 1999-2007 | 0.2 |   |  .32 |   | 2007-2014 | 1.6 | ¶  | <.001 |   |  |   |   |   |   | 1.6 | ¶  | <.001 |
|  Oral cavity and pharynx | 1999-2005 | -0.2 |  |  .59 |  | 2005-2014 | 1.3 | ¶  | <.001 |  |  |  |  |  |  | 1.3 | ¶  | <.001 |
|  Pancreas | 1999-2014 | 1.0 | ¶  | <.001 |   |  |   |   |   |   |  |   |   |   |   | 1.0 | ¶  | <.001 |
|  Liver and intrahepatic bile duct | 1999-2009 | 4.4 | ¶  | <.001 |  | 2009-2014 | 2.8 | ¶  | <.001 |  |  |  |  |  |  | 2.8 | ¶  | <.001 |
|  Stomach | 1999-2007 | -1.8 | ¶  | <.001 |   | 2007-2014 | -0.3 |   |  .13 |   |  |   |   |   |   | -0.3 |   |  .13 |
|  Myeloma | 1999-2007 | 1.2 | ¶  | <.001 |  | 2007-2014 | 2.5 | ¶  | <.001 |  |  |  |  |  |  | 2.5 | ¶  | <.001 |
|  Esophagus | 1999-2007 | 0.3 |   |  .26 |   | 2007-2014 | -1.6 | ¶  | <.001 |   |  |   |   |   |   | -1.6 | ¶  | <.001 |
|  Brain and other nervous system | 1999-2014 | -0.2 | ¶  |  .003 |  |  |  |  |  |  |  |  |  |  |  | -0.2 | ¶  |  .003 |
|  Thyroid | 1999-2009 | 6.8 | ¶  | <.001 |   | 2009-2014 | 2.4 | ¶  | <.001 |   |  |   |   |   |   | 2.4 | ¶  | <.001 |
|  Larynx | 1999-2014 | -2.3 | ¶  | <.001 |  |  |  |  |  |  |  |  |  |  |  | -2.3 | ¶  | <.001 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Supporting Table 1 (continued)

|  |  |
| --- | --- |
|  | Joinpoint Analyses (1999–2014)† |
|  | Trend 1 |  | Trend 2 |  | Trend 3 |  | AAPC‡ |
| Sex/Cancer Site or Type | Years | APC§ |  | P |  | Years | APC§ |  | P |  | Years | APC§ |  | P |  | 2010–2014 | P |
| Top 18 cancers for females\*\* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Breast | 1999-2004 | -2.2 | ¶  | <.001 |  | 2004-2014 | 0.4 | ¶  |  .008 |  |  |  |  |  |  | 0.4 | ¶  |  .008 |
|  Lung and bronchus | 1999-2006 | 0.7 | ¶  | <.001 |   | 2006-2014 | -1.2 | ¶  | <.001 |   |  |   |   |   |   | -1.2 | ¶  | <.001 |
|  Colon and rectum | 1999-2006 | -2.0 | ¶  | <.001 |  | 2006-2012 | -3.4 | ¶  | <.001 |  | 2012-2014 | -0.1 |  |  .94 |  | -1.7 | ¶  |  .004 |
|  Corpus and uterus, NOS | 1999-2003 | -0.6 |   |  .13 |   | 2003-2014 | 1.2 | ¶  | <.001 |   |  |   |   |   |   | 1.2 | ¶  | <.001 |
|  Thyroid | 1999-2009 | 7.4 | ¶  | <.001 |  | 2009-2014 | 1.9 | ¶  | <.001 |  |  |  |  |  |  | 1.9 | ¶  | <.001 |
|  Melanoma of the skin | 1999-2005 | 3.8 | ¶  | <.001 |   | 2005-2014 | 1.2 | ¶  |  .002 |   |  |   |   |   |   | 1.2 | ¶  |  .002 |
|  Non-Hodgkin lymphoma | 1999-2004 | 0.8 | ¶  |  .03 |  | 2004-2014 | -0.4 | ¶  |  .002 |  |  |  |  |  |  | -0.4 | ¶  |  .002 |
|  Ovary|| | 1999-2014 | -1.6 | ¶  | <.001 |   |  |   |   |   |   |  |   |   |   |   | -1.6 | ¶  | <.001 |
|  Leukemia | 1999-2005 | 0.3 |  |  .42 |  | 2005-2014 | 1.4 | ¶  | <.001 |  |  |  |  |  |  | 1.4 | ¶  | <.001 |
|  Kidney and renal pelvis | 1999-2006 | 3.9 | ¶  | <.001 |   | 2006-2014 | 0.4 | ¶  |  .03 |   |  |   |   |   |   | 0.4 | ¶  |  .03 |
|  Pancreas | 1999-2014 | 1.1 | ¶  | <.001 |  |  |  |  |  |  |  |  |  |  |  | 1.1 | ¶  | <.001 |
|  Urinary bladder | 1999-2014 | -0.8 | ¶  | <.001 |   |  |   |   |   |   |  |   |   |   |   | -0.8 | ¶  | <.001 |
|  Cervix uteri | 1999-2003 | -3.9 | ¶  | <.001 |  | 2003-2014 | -1.0 | ¶  | <.001 |  |  |  |  |  |  | -1.0 | ¶  | <.001 |
|  Oral cavity and pharynx | 1999-2004 | -0.6 |   |  .18 |   | 2004-2014 | 0.8 | ¶  | <.001 |   |  |   |   |   |   | 0.8 | ¶  | <.001 |
|  Myeloma | 1999-2007 | 0.4 | ¶  |  .03 |  | 2007-2010 | 3.6 | ¶  |  .02 |  | 2010-2014 | 1.6 | ¶  |  .003 |  | 1.6 | ¶  |  .003 |
|  Brain and other nervous system | 1999-2007 | 0.2 |   |  .33 |   | 2007-2014 | -0.7 | ¶  |  .008 |   |  |   |   |   |   | -0.7 | ¶  |  .008 |
|  Stomach | 1999-2008 | -1.1 | ¶  | <.001 |  | 2008-2014 | 0.1 |  |  .77 |  |  |  |  |  |  | 0.1 |  |  .77 |
|  Liver and intrahepatic bile duct | 1999-2001 | -2.4 |   |  .45 |   | 2001-2014 | 3.8 | ¶  | <.001 |   |  |   |   |   |   | 3.8 | ¶  | <.001 |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Abbreviations: AAPC, average annual percent change; APC, annual percent change; NOS, not otherwise specified. |  |  |  |  |  |  |
| \* Source: NPCR and SEER areas reported by NAACCR as meeting high-quality incidence data standards for the specified time periods. |  |  |  |  |  |  |
| †  Joinpoint models with up to two joinpoints are based on rates per 100,000 persons age standardized to the 2000 US standard population (19 age groups - Census P25–1130). Joinpoint Regression Program, Version 4.4.0.0 January 2017, Statistical Research and Applications Branch, National Cancer Institute.  |
| ‡  AAPC is the average annual percent change and is a weighted average of the annual percent change (APCs) over the fixed interval 2010-2014 using the underlying Joinpoint model for the period of 1999-2014.  |  |  |  |  |  |  |
| § The APC is based on rates that were age-adjusted to the 2000 US standard population (19 age groups, Census publication p25–1130). |  |  |  |  |  |  |
| || All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors. |  |  |  |  |  |  |
| ¶  The APC or AAPC is statistically significantly different from zero (2-sided *t* test; *P* < .05). |  |  |  |  |  |  |
| \*\* Cancers are listed in descending rank order of sex-specific, age-adjusted incidence rates for 2010-2014 for all racial and ethnic groups combined (using data from the National Program of Cancer Registries [NPCR] and SEER Program areas reported by the North American Association of Central Cancer Registries [NAACCR] as meeting high-quality incidence data standards for 1999–2014). More than 15 cancers may appear under men and women to include the top 15 cancers in each racial and ethnic group. |
| Registries included in the Joinpoint models (1999-2014) for all races/ethnicities (42 states): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming. |

**Supporting Table 2**. Joinpoint mortality trends for the most common cancers, all races and ethnicities combined, by sex, 1999-2015\*

|  |
| --- |
| Joinpoint Analyses (1999–2015)† |
|  | Trend 1 |  | Trend 2 |  | Trend 3 |  | Trend 4 |  | AAPC‡ |
| Sex/Cancer Site or Type | Years | APC§  |  | P |   | Years | APC§  |  | P |  | Years | APC§  |  | P |   | Years | APC§  |  | P |   | 2011-2015 | P |
| All sites |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Both sexes | 1999-2001 | -1.0 | || |  .01 |  | 2001-2015 | -1.5 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -1.5 | || | <.001 |
|  Males | 1999-2015 | -1.8 | || | <.001 |   |  |   |   |   |  |  |   |   |   |   |   |   |   |   |   | -1.8 | || | <.001 |
|  Females | 1999-2002 | -0.9 | || |  .001 |  | 2002-2015 | -1.4 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -1.4 | || | <.001 |
|  Children (ages 0-14) | 1999-2015 | -1.5 | || | <.001 |   |  |   |   |   |  |  |   |   |   |   |   |   |   |   |   | -1.5 | || | <.001 |
|  Children (ages 0-19) | 1999-2015 | -1.6 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -1.6 | || | <.001 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Top 18 cancers for males¶  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Lung and Bronchus | 1999-2005 | -1.8 | || | <.001 |  | 2005-2012 | -3.0 | || | <.001 |  | 2012-2015 | -4.0 | || | <.001 |  |  |  |  |  |  | -3.8 | || | <.001 |
|  Prostate | 1999-2013 | -3.5 | || | <.001 |   | 2013-2015 | -0.9 |   |  .62 |  |  |   |   |   |   |   |   |   |   |   | -2.2 | || |  .01 |
|  Colon and Rectum | 1999-2002 | -2.0 | || |  .001 |  | 2002-2005 | -4.1 | || |  .001 |  | 2005-2015 | -2.5 | || | <.001 |  |  |  |  |  |  | -2.5 | || | <.001 |
|  Pancreas | 1999-2015 | 0.2 | || | <.001 |   |  |   |   |   |  |  |   |   |   |   |   |   |   |   |   | 0.2 | || | <.001 |
|  Liver and Intrahepatic Bile Duct | 1999-2013 | 2.7 | || | <.001 |  | 2013-2015 | 0.5 |  |  .73 |  |  |  |  |  |  |  |  |  |  |  | 1.6 | || |  .03 |
|  Leukemia | 1999-2013 | -0.9 | || | <.001 |   | 2013-2015 | -3.5 | || |  .003 |  |  |   |   |   |   |   |   |   |   |   | -2.2 | || | <.001 |
|  Urinary Bladder | 1999-2013 | 0.0 |  |  .52 |  | 2013-2015 | -1.4 |  |  .22 |  |  |  |  |  |  |  |  |  |  |  | -0.7 |  |  .21 |
|  Non-Hodgkin Lymphoma | 1999-2006 | -2.9 | || | <.001 |   | 2006-2015 | -2.0 | || | <.001 |  |  |   |   |   |   |   |   |   |   |   | -2.0 | || | <.001 |
|  Esophagus | 1999-2005 | 0.4 |  |  .12 |  | 2005-2015 | -1.1 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -1.1 | || | <.001 |
|  Kidney and Renal Pelvis | 1999-2001 | 2.7 | || |  .02 |   | 2001-2006 | -1.4 | || |  .001 |  | 2006-2015 | -0.5 | || | <.001 |   |   |   |   |   |   | -0.5 | || | <.001 |
|  Brain and Other Nervous System | 1999-2006 | -1.3 | || | <.001 |  | 2006-2015 | 0.5 | || |  .01 |  |  |  |  |  |  |  |  |  |  |  | 0.5 | || |  .01 |
|  Stomach | 1999-2011 | -3.2 | || | <.001 |   | 2011-2015 | -1.6 | || |  .01 |  |  |   |   |   |   |   |   |   |   |   | -1.6 | || |  .01 |
|  Myeloma | 1999-2015 | -0.9 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -0.9 | || | <.001 |
|  Melanoma of the Skin | 1999-2009 | 0.9 | || | <.001 |   | 2009-2013 | -0.9 |   |  .31 |  | 2013-2015 | -5.0 | || |  .01 |   |   |   |   |   |   | -3.0 | || |  .001 |
|  Oral Cavity and Pharynx | 1999-2009 | -1.2 | || | <.001 |  | 2009-2015 | 1.0 | || |  .04 |  |  |  |  |  |  |  |  |  |  |  | 1.0 | || |  .04 |
|  Larynx | 1999-2015 | -2.5 | || | <.001 |   |  |   |   |   |  |  |   |   |   |   |   |   |   |   |   | -2.5 | || | <.001 |
|  Non-Melanoma Skin | 1999-2008 | 0.2 |  |  .68 |  | 2008-2015 | 2.8 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | 2.8 | || | <.001 |
|  Soft Tissue including Heart | 1999-2002 | -2.5 |   |  .09 |   | 2002-2015 | 0.8 | || | <.001 |  |  |   |   |   |   |   |   |   |   |   | 0.8 | || | <.001 |

Supporting Table 2 (cont.)

|  |
| --- |
| Joinpoint Analyses (1999–2015)† |
|  | Trend 1 |  | Trend 2 |  | Trend 3 |  | Trend 4 |  | AAPC‡ |
| Sex/Cancer Site or Type | Years | APC§ |  | P |  | Years | APC§ |  | P |  | Years | APC§ |  | P |  | Years | APC§ |  | P |  | 2011–2015 | P |
| Top 20 cancers for females¶  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Lung and Bronchus | 1999-2002 | 1.0 | || |  .04 |  | 2002-2007 | -0.8 | || |  .02 |  | 2007-2012 | -1.9 | || | <.001 |  | 2012-2015 | -2.6 | || |  .001 |  | -2.4 | || | <.001 |
|  Breast | 1999-2003 | -1.5 | || | <.001 |   | 2003-2007 | -2.4 | || | <.001 |  | 2007-2015 | -1.6 | || | <.001 |   |  |   |   |   |   | -1.6 | || | <.001 |
|  Colon and Rectum | 1999-2015 | -2.7 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -2.7 | || | <.001 |
|  Pancreas | 1999-2015 | 0.2 | || | <.001 |   |  |   |   |   |  |  |   |   |   |   |  |   |   |   |   | 0.2 | || | <.001 |
|  Ovary | 1999-2003 | 0.6 |  |  .15 |  | 2003-2015 | -2.3 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -2.3 | || | <.001 |
|  Leukemia | 1999-2013 | -1.2 | || | <.001 |   | 2013-2015 | -3.5 | || |  .03 |  |  |   |   |   |   |  |   |   |   |   | -2.3 | || |  .001 |
|  Corpus and Uterus, NOS | 1999-2008 | 0.3 |  |  .14 |  | 2008-2015 | 1.9 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | 1.9 | || | <.001 |
|  Non-Hodgkin Lymphoma | 1999-2005 | -3.6 | || | <.001 |   | 2005-2015 | -2.7 | || | <.001 |  |  |   |   |   |   |  |   |   |   |   | -2.7 | || | <.001 |
|  Liver and Intrahepatic Bile Duct | 1999-2008 | 1.5 | || | <.001 |  | 2008-2015 | 2.7 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | 2.7 | || | <.001 |
|  Brain and Other Nervous System | 1999-2006 | -1.3 | || |  .001 |   | 2006-2015 | 0.5 | || |  .03 |  |  |   |   |   |   |  |   |   |   |   | 0.5 | || |  .03 |
|  Myeloma | 1999-2009 | -2.1 | || | <.001 |  | 2009-2015 | 0.0 |  |  .92 |  |  |  |  |  |  |  |  |  |  |  | 0.0 |  |  .92 |
|  Kidney and Renal Pelvis | 1999-2001 | 2.8 |   |  .33 |   | 2001-2015 | -1.4 | || | <.001 |  |  |   |   |   |   |  |   |   |   |   | -1.4 | || | <.001 |
|  Stomach | 1999-2008 | -2.9 | || | <.001 |  | 2008-2015 | -1.8 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  | -1.8 | || | <.001 |
|  Cervix Uteri | 1999-2004 | -3.2 | || | <.001 |   | 2004-2015 | -0.7 | || |  .001 |  |  |   |   |   |   |  |   |   |   |   | -0.7 | || |  .001 |
|  Urinary Bladder | 1999-2015 | -0.5 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -0.5 | || | <.001 |
|  Melanoma of the Skin | 1999-2012 | -0.4 |   |  .06 |   | 2012-2015 | -3.4 |   |  .07 |  |  |   |   |   |   |  |   |   |   |   | -2.6 | || |  .04 |
|  Esophagus | 1999-2015 | -1.6 | || | <.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | -1.6 | || | <.001 |
|  Oral Cavity and Pharynx | 1999-2015 | -1.3 | || | <.001 |   |  |   |   |   |  |  |   |   |   |   |  |   |   |   |   | -1.3 | || | <.001 |
|  Soft Tissue including Heart | 1999-2002 | -2.1 | || |  .03 |  | 2002-2015 | 0.1 |  |  .11 |  |  |  |  |  |  |  |  |  |  |  | 0.1 |  |  .11 |
|  Gallbladder | 1999-2015 | -1.3 | || | <.001 |   |  |   |   |   |  |  |   |   |   |   |  |   |   |   |   | -1.3 | || | <.001 |

|  |
| --- |
| Abbreviations: AAPC, average annual percent change; APC, annual percent change; NCHS, National Center for Health Statistics; NOS, not otherwise specified. |
| \* Source: NCHS public-use data file for the total US, 1975–2015. |
| † Joinpoint models with up to three joinpoints are based on rates per 100,000 persons age standardized to the 2000 US standard population (19 age groups - Census P25–1130). Joinpoint Regression Program, Version 4.5.0.1. June 2017, Statistical Research and Applications Branch, National Cancer Institute.  |
| ‡ AAPC is the average annual percent change and is a weighted average of the annual percent change (APCs) over the fixed interval 2011-2015 using the underlying Joinpoint model for the period of 1999-2015.  |
| § The APC is based on rates that were age-adjusted to the 2000 US standard population (19 age groups, Census publication p25–1130). |
| || The APC or AAPC is statistically significantly different from zero (2-sided t test; P <.05). |
| ¶ Cancers are listed in descending rank order of sex-specific, age-adjusted death rates for 2011-2015 for all racial and ethnic groups combined. More than 15 cancers may appear under men and women to include the top 15 cancers in each racial and ethnic group. |